Renal toxicity and chemotherapy in children with cancer

Ruggiero, Antonio; Ferrara, Pietro; Attinà, Giorgio; Rizzo, Daniela; Riccardi, Riccardo

doi:10.1111/bcp.13388

Cited by 66 publications

(52 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The toxicity of cisplatin and ifosfamide observed in this study is consistent with that previously reported in larger cohorts, 3 However, the final equation does not exactly match the previously proposed Bouvet equation 7 : age was significant in the initial part (ie, univariate testing) of the current PK analysis but appeared to be redundant with body weight when the full model was tested, and thus was removed in the final model. Moreover, the exponents corresponding to each covariate of the current final model were not exactly the same as those in the previously proposed equation.…”

Section: F I G U R E 1 Correlation Between Actual 51supporting

confidence: 67%

“…2 A recent systematic review on early and late renal adverse effects after nephrotoxic treatment reported an incidence of drug-induced chronic renal damage of 1.4-30% in ifosfamide use and of 10-80% in cisplatin use. 3 Major risk factors in the pediatric population included being less injuries. [8][9][10] For all these reasons, this study prospectively evaluates the Schwartz equations with or without PcysC in children with cancer treated by cisplatin and/or ifosfamide to monitor the change of GFR during chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide

Lambert

White-Koning

Alonso

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Plasma cystatin C is a potential marker of the glomerular filtration rate (GFR), and urinary cystatin C has been proposed as a marker of tubular dysfunction. Procedure: A prospective study (NCT02822404) was conducted to assess the benefit of considering cystatin C plasma and urinary levels to better evaluate cisplatin and/or ifosfamide renal toxicity in children with cancer. Plasma 51 Cr-EDTA clearance as a marker of GFR and urinary markers of tubular toxicity were monitored in 40 children treated by cisplatin and/or ifosfamide. Several equations previously proposed to estimate GFR, with or without inclusion of plasma cystatin C level, were compared. A population pharmacokinetic approach was also used to analyze plasma 51 Cr-EDTA data, and evaluate the relationship between patient covariates (including plasma cystatin C level) and GFR during the course of chemotherapy treatment. Results: Equations including plasma cystatin C described GFR changes during chemotherapy better than those without this variable. An equation based on plasma cystatin C, serum creatinine, and body weight enabled us to accurately describe the evolution of GFR during chemotherapy. The urinary cystatin C/creatinine ratio was compared between children with or without tubular toxicity, according to a standard assessment of tubular dysfunction. However, although the urinary cystatin C/creatinine ratio was increased in children with tubular toxicity, this marker does not provide additional information to the well-known markers of tubulopathy. Conclusions: Monitoring of plasma cystatin C may be substituted to radionucleide glomerular exploration in children treated by cisplatin and/or ifosfamide.

show abstract

Section: F I G U R E 1 Correlation Between Actual 51supporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide

Lambert

White-Koning

Alonso

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Hematopoietic stem cell transplants (HSCT) in patients younger than 20 years are performed in more than 2500 patients annually in the United States 2 . Pediatric patients with oncologic disease and/or HSCT are at high risk for developing life‐threatening illnesses with severely compromised immune systems 3 and organ dysfunction 4‐10 . Patients with oncologic disease account for approximately 4% of all pediatric intensive care unit (PICU) admissions and 11% of PICU deaths 11 .…”

Section: Introductionmentioning

confidence: 99%

Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience

Steppan

Coleman

Viamonte

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Outcomes for patients with oncologic disease and/or after hematopoietic stem cell transplant (HSCT) requiring intensive care unit admission have improved, but indications for and outcomes after extracorporeal membrane oxygenation (ECMO) support in this population are poorly characterized. Procedure We analyzed data from consecutive patients < 18 years with oncologic disease and/or after HSCT reported to a pediatric ECMO registry by nine pediatric centers in the United States between 2011 and 2018. Results We identified 18 ECMO patients with oncologic disease and/or HSCT, and 415 ECMO controls matched with a propensity score algorithm based on age, gender, race, severity of illness at admission, and reason for ECMO. The primary indication for ECMO was respiratory failure in 66.7% in the oncologic disease and/or HSCT group, and in 70.7% in the matched ECMO control group. Eleven of 18 patients survived to hospital discharge (61.1%), similar to the matched control group (60.8%), P = 0.979. Children with oncologic disease and/or HSCT had lower mean platelet counts during ECMO and received higher volumes of platelets compared with the control group, mean 14.6 mL/kg/day (standard deviations [SD], 9.8) versus mean 9.3 mL/kg/day (SD, 10.4), P = 0.001. Of the 11 surviving children with oncologic disease and/or HSCT, five sustained new neurologic disorders (45.5%) versus 45 of 222 (20.3%) in the control group, P = 0.061. Bleeding complications were similar in the two groups. Conclusions Outcomes of patients with oncologic disease and/or HSCT supported on ECMO in the current era are not significantly different compared with matched ECMO controls and are improved from previously published reports.

show abstract

“…In CP-induced nephrotoxicity increase plasma CREA [creatinine] and BUN [Blood Urea Nitrogen] levels, which indicates renal glomerular dysfunction. However, despite the severe toxicity of cyclophosphamide in experimental animal and human studies [6,7], still clinicians prescribe it as the first line treatment for cancer patients. Also, exogenous antioxidant agents were revealed effective in mitigation of CP nephrotoxicity [6,8].…”

Section: Introductionmentioning

confidence: 99%

Nephroprotective effect of cerium oxide nanoparticles on cyclophosphamide-induced nephrotoxicity via anti-apoptotic and antioxidant properties in BALB/c mice

Hamzeh¹,

Amiri²,

Beklar³

et al. 2018

mpj

View full text Add to dashboard Cite

Cyclophosphamide [CP], as alkylating agents has side effects such as nephrotoxicity. Cerium oxide nanoparticles [nanoceria; NC], as an antioxidant, are effective at reduction oxidative stress. This study evaluated the protective effect of nanoceria in nephrotoxicity induced CP. 32 BALB/c mice were randomly divided into four equal groups. Control, NC, CP and NC+CP. NC and CP injected intraperitoneally respectively in dose of 100 μg/kg for 3 days and 200 mg/kg single dose on 3th day of study. Two days after the final treatment, histochemical, serum biochemical, histopathological and immunohistochemical examinations were performed for determination effects of NC on nephrotoxicity. Oxidative stress and renal injury induced in CP treated mice were proved by the significantly elevation of urea and creatinine and alteration in oxidative stress markers [MDA and GSH levels]. Consequently, histopathological changes and apoptosis were markedly increased. NC was able to reduce MDA, urea , creatinine and increase GSH content. In addition, NC pretreatment could alleviated immunoreactivity of caspase-3. NC revealed a strong antioxidant in nephrotoxicity following CP treatment. This study suggests that NC through antioxidant and antiapoptotic properties have protective effect against CP-induced nephrotoxicity.

show abstract

Renal toxicity and chemotherapy in children with cancer

Cited by 66 publications

References 85 publications

Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide

Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide

Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience

Nephroprotective effect of cerium oxide nanoparticles on cyclophosphamide-induced nephrotoxicity via anti-apoptotic and antioxidant properties in BALB/c mice

Contact Info

Product

Resources

About